25 XP   0   0   10

Nuvalent Inc
Buy, Hold or Sell?

Let's analyse Nuvalent together

PenkeI guess you are interested in Nuvalent Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Nuvalent Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Nuvalent Inc

I send you an email if I find something interesting about Nuvalent Inc.

Quick analysis of Nuvalent (30 sec.)










What can you expect buying and holding a share of Nuvalent? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$11.27
Expected worth in 1 year
$14.64
How sure are you?
30.8%

+ What do you gain per year?

Total Gains per Share
$3.37
Return On Investment
5.1%

For what price can you sell your share?

Current Price per Share
$66.07
Expected price per share
$41.16 - $71.65
How sure are you?
50%

1. Valuation of Nuvalent (5 min.)




Live pricePrice per Share (EOD)

$66.07

Intrinsic Value Per Share

$-27.39 - $-32.49

Total Value Per Share

$-16.12 - $-21.22

2. Growth of Nuvalent (5 min.)




Is Nuvalent growing?

Current yearPrevious yearGrowGrow %
How rich?$700.5m$305.3m$185m37.7%

How much money is Nuvalent making?

Current yearPrevious yearGrowGrow %
Making money-$30.3m-$18.6m-$11.6m-38.6%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Nuvalent (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#75 / 1010

Most Revenue
#730 / 1010

Most Profit
#797 / 1010

Most Efficient
#160 / 1010

What can you expect buying and holding a share of Nuvalent? (5 min.)

Welcome investor! Nuvalent's management wants to use your money to grow the business. In return you get a share of Nuvalent.

What can you expect buying and holding a share of Nuvalent?

First you should know what it really means to hold a share of Nuvalent. And how you can make/lose money.

Speculation

The Price per Share of Nuvalent is $66.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nuvalent.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nuvalent, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $11.27. Based on the TTM, the Book Value Change Per Share is $0.84 per quarter. Based on the YOY, the Book Value Change Per Share is $0.76 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nuvalent.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.62-0.9%-0.53-0.8%-0.35-0.5%-0.34-0.5%-0.34-0.5%
Usd Book Value Change Per Share4.516.8%0.841.3%0.761.1%0.871.3%0.871.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.516.8%0.841.3%0.761.1%0.871.3%0.871.3%
Usd Price Per Share73.59-46.96-19.17-23.54-23.54-
Price to Earnings Ratio-29.88--21.58--13.38--14.05--14.05-
Price-to-Total Gains Ratio16.31--69.90--40.55--50.74--50.74-
Price to Book Ratio6.53-5.66-3.69-3.52-3.52-
Price-to-Total Gains Ratio16.31--69.90--40.55--50.74--50.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share66.07
Number of shares15
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.840.87
Usd Total Gains Per Share0.840.87
Gains per Quarter (15 shares)12.6413.00
Gains per Year (15 shares)50.5552.00
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10514105242
2010192010494
301521430156146
402021940208198
502532450260250
603032960312302
703543470364354
804043980416406
904554490468458
1005055000520510

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%4.09.00.030.8%4.09.00.030.8%4.09.00.030.8%

Fundamentals of Nuvalent

About Nuvalent Inc

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2024-04-11 16:18:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Nuvalent Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nuvalent earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Nuvalent Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y54.7%-54.7%
5Y54.7%10Y54.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM--216.8%+216.8%
YOY--282.3%+282.3%
5Y54.7%-436.8%+491.5%
10Y54.7%-597.3%+652.0%
1.1.2. Return on Assets

Shows how efficient Nuvalent is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • -5.2% Return on Assets means that Nuvalent generated $-0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Nuvalent Inc:

  • The MRQ is -5.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.2%TTM-6.0%+0.8%
TTM-6.0%YOY-6.2%+0.2%
TTM-6.0%5Y-13.2%+7.2%
5Y-13.2%10Y-13.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.2%-13.3%+8.1%
TTM-6.0%-12.8%+6.8%
YOY-6.2%-11.6%+5.4%
5Y-13.2%-13.8%+0.6%
10Y-13.2%-15.6%+2.4%
1.1.3. Return on Equity

Shows how efficient Nuvalent is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • -5.5% Return on Equity means Nuvalent generated $-0.05 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Nuvalent Inc:

  • The MRQ is -5.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.4%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-5.5%TTM-6.4%+0.9%
TTM-6.4%YOY-6.5%+0.1%
TTM-6.4%5Y-9.0%+2.7%
5Y-9.0%10Y-9.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5.5%-16.9%+11.4%
TTM-6.4%-16.1%+9.7%
YOY-6.5%-14.9%+8.4%
5Y-9.0%-19.3%+10.3%
10Y-9.0%-20.1%+11.1%

1.2. Operating Efficiency of Nuvalent Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nuvalent is operating .

  • Measures how much profit Nuvalent makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Nuvalent Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y39.9%-39.9%
5Y39.9%10Y39.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM--238.5%+238.5%
YOY--288.4%+288.4%
5Y39.9%-486.2%+526.1%
10Y39.9%-628.4%+668.3%
1.2.2. Operating Ratio

Measures how efficient Nuvalent is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Nuvalent Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.550+0.550
5Y-0.55010Y-0.5500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM-3.310-3.310
YOY-3.838-3.838
5Y-0.5505.679-6.229
10Y-0.5507.823-8.373

1.3. Liquidity of Nuvalent Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nuvalent is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 22.83 means the company has $22.83 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Nuvalent Inc:

  • The MRQ is 22.829. The company is very able to pay all its short-term debts. +2
  • The TTM is 21.269. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ22.829TTM21.269+1.560
TTM21.269YOY25.753-4.484
TTM21.2695Y22.833-1.564
5Y22.83310Y22.8330.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ22.8293.863+18.966
TTM21.2694.169+17.100
YOY25.7535.337+20.416
5Y22.8336.122+16.711
10Y22.8336.434+16.399
1.3.2. Quick Ratio

Measures if Nuvalent is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • A Quick Ratio of 34.71 means the company can pay off $34.71 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Nuvalent Inc:

  • The MRQ is 34.705. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 36.442. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ34.705TTM36.442-1.737
TTM36.442YOY42.480-6.038
TTM36.4425Y35.195+1.248
5Y35.19510Y35.1950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ34.7053.504+31.201
TTM36.4423.991+32.451
YOY42.4805.371+37.109
5Y35.1956.088+29.107
10Y35.1956.395+28.800

1.4. Solvency of Nuvalent Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nuvalent assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nuvalent to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that Nuvalent assets are financed with 4.3% credit (debt) and the remaining percentage (100% - 4.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Nuvalent Inc:

  • The MRQ is 0.043. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.049. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.043TTM0.049-0.006
TTM0.049YOY0.040+0.009
TTM0.0495Y0.453-0.404
5Y0.45310Y0.4530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0430.339-0.296
TTM0.0490.337-0.288
YOY0.0400.271-0.231
5Y0.4530.368+0.085
10Y0.4530.388+0.065
1.4.2. Debt to Equity Ratio

Measures if Nuvalent is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nuvalent to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.5% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Nuvalent Inc:

  • The MRQ is 0.045. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.052. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.045TTM0.052-0.006
TTM0.052YOY0.042+0.010
TTM0.0525Y0.053-0.001
5Y0.05310Y0.0530.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0450.392-0.347
TTM0.0520.403-0.351
YOY0.0420.335-0.293
5Y0.0530.427-0.374
10Y0.0530.461-0.408

2. Market Valuation of Nuvalent Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nuvalent generates.

  • Above 15 is considered overpriced but always compare Nuvalent to the Biotechnology industry mean.
  • A PE ratio of -29.88 means the investor is paying $-29.88 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Nuvalent Inc:

  • The EOD is -26.823. Based on the earnings, the company is expensive. -2
  • The MRQ is -29.876. Based on the earnings, the company is expensive. -2
  • The TTM is -21.583. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-26.823MRQ-29.876+3.053
MRQ-29.876TTM-21.583-8.293
TTM-21.583YOY-13.382-8.201
TTM-21.5835Y-14.047-7.537
5Y-14.04710Y-14.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-26.823-2.300-24.523
MRQ-29.876-2.656-27.220
TTM-21.583-2.718-18.865
YOY-13.382-4.145-9.237
5Y-14.047-6.258-7.789
10Y-14.047-6.315-7.732
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Nuvalent Inc:

  • The EOD is -34.000. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -37.870. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -27.695. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-34.000MRQ-37.870+3.870
MRQ-37.870TTM-27.695-10.175
TTM-27.695YOY-17.027-10.668
TTM-27.6955Y-17.648-10.047
5Y-17.64810Y-17.6480.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-34.000-2.974-31.026
MRQ-37.870-3.306-34.564
TTM-27.695-3.508-24.187
YOY-17.027-5.613-11.414
5Y-17.648-8.378-9.270
10Y-17.648-8.873-8.775
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nuvalent is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.53 means the investor is paying $6.53 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Nuvalent Inc:

  • The EOD is 5.865. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.532. Based on the equity, the company is overpriced. -1
  • The TTM is 5.664. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.865MRQ6.532-0.667
MRQ6.532TTM5.664+0.868
TTM5.664YOY3.690+1.974
TTM5.6645Y3.517+2.147
5Y3.51710Y3.5170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8651.914+3.951
MRQ6.5322.116+4.416
TTM5.6642.097+3.567
YOY3.6902.881+0.809
5Y3.5173.550-0.033
10Y3.5173.936-0.419
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Nuvalent Inc.

3.1. Institutions holding Nuvalent Inc

Institutions are holding 108.896% of the shares of Nuvalent Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Deerfield Management Co31.20320.24741999102400
2023-12-31FMR Inc13.61850.04938725070110545714.508
2023-12-31Paradigm Biocapital Advisors LP6.021813.292238580082219861135.5105
2023-12-31Bain Capital Life Sciences Investors, LLC5.583625.2336357726700
2023-12-31Vanguard Group Inc5.2130.00543339850120566856.4932
2023-12-31Perceptive Advisors LLC4.55454.7932291799145454018.4514
2023-12-31BlackRock Inc4.24740.0051272119529121611.9843
2023-12-31Fairmount Funds Management LLC3.004114.96461924626-527193-21.5021
2023-12-31State Street Corporation2.65540.0061170123444076834.9687
2023-12-31COMMODORE CAPITAL LP2.07758.5587133103750225960.6024
2023-12-31Boxer Capital LLC1.74854.10871120192-90000-7.4368
2023-12-31T. Rowe Price Associates, Inc.1.72690.0109110638229944637.109
2023-12-31Wellington Management Company LLP1.58180.01391013402-542965-34.8867
2023-12-31Driehaus Capital Management LLC1.46370.8313937728-301675-24.3403
2023-12-31Geode Capital Management, LLC1.0220.00565474710939820.0602
2023-12-31Lord, Abbett & Co LLC0.70890.124541514541510
2023-12-31Deep Track Capital, LP0.70241.10594500004500000
2023-12-31Goldman Sachs Group Inc0.68250.0029437258357153445.8561
2023-12-31Soleus Capital Management, L.P.0.5042.6365322888168472109.1027
2023-12-31Fred Alger Management, LLC0.50250.1278321952241915302.254
Total 88.82296.118556906002+6838471+12.0%

3.2. Funds holding Nuvalent Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O3.86350.26542475174468001.9272
2024-02-29Fidelity Growth Company Fund2.64870.23921696902813005.0322
2024-02-29Vanguard Total Stock Mkt Idx Inv1.66970.00581069710-3472-0.3235
2024-03-28SPDR® S&P Biotech ETF1.41330.9004905403114401.2797
2024-02-29Vanguard Small Cap Index1.38010.052988414282620.9433
2024-02-29Fidelity Select Health Care1.01480.6909650121116211.82
2024-03-28iShares Russell 2000 ETF1.01370.07456494053120.0481
2024-02-29Vanguard Small Cap Value Index Inv0.94250.095560381842530.7093
2024-02-29Fidelity Growth Company K60.93990.275560213493001.5687
2024-01-31Fidelity Small Cap Growth0.85630.7194548613-662-0.1205
2024-02-29Fidelity Series Growth Company0.77920.2659499225181653.776
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.73260.03874693353210.0684
2024-02-29Fidelity Advisor Health Care I0.66390.718942530000
2023-12-31US Small-Cap Growth II Equity Comp0.64560.122641361613068746.1907
2023-12-31T. Rowe Price New Horizons0.64560.12341361613068746.1907
2024-02-29Lord Abbett Developing Growth A0.54421.17434863800
2024-02-29Fidelity Advisor Biotechnology I0.53251.613934117727000.7977
2024-02-29Fidelity Advisor Growth Opps M0.52910.140633897600
2023-12-31T. Rowe Price Health Sciences0.46910.15033005483005480
2024-01-31Fidelity Small Cap Index0.41960.081526880347461.7973
Total 21.70397.748913904656+757008+5.4%

3.3. Insider Transactions

Insiders are holding 3.761% of the shares of Nuvalent Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08Matthew ShairSELL3750068.44
2024-04-04Deborah Ann MillerSELL300073.6
2024-04-01Matthew ShairSELL3750076.92
2024-03-28Deborah Ann MillerSELL2200075.2
2024-03-27Andrew A F HackSELL88000072.77
2024-03-25Matthew ShairSELL3750076.77
2024-03-22Darlene NociSELL2000077.51
2023-12-28Matthew ShairSELL4854875.46
2023-12-26Matthew ShairSELL6960275.12
2023-12-18Alexandra BalcomSELL3000075.82
2023-12-18Anna ProtopapasSELL500075.67
2023-12-18Darlene NociSELL4000075.82
2023-11-28Matthew ShairSELL915061.89
2023-11-01Darlene NociSELL300052.66
2023-10-24Matthew ShairSELL9170050.7
2023-10-04Christopher Durant TurnerSELL799554.04
2023-10-02Darlene NociSELL300045.88
2023-09-15Deborah Ann MillerSELL200047.64
2023-09-01Darlene NociSELL300046.56
2023-08-01Darlene NociSELL300049.95

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Nuvalent Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.5130.842+436%0.759+495%0.867+421%0.867+421%
Book Value Per Share--11.2668.194+37%5.208+116%4.805+134%4.805+134%
Current Ratio--22.82921.269+7%25.753-11%22.8330%22.8330%
Debt To Asset Ratio--0.0430.049-11%0.040+9%0.453-90%0.453-90%
Debt To Equity Ratio--0.0450.052-12%0.042+9%0.053-14%0.053-14%
Dividend Per Share----0%-0%-0%-0%
Eps---0.616-0.529-14%-0.349-43%-0.340-45%-0.340-45%
Free Cash Flow Per Share---0.486-0.418-14%-0.277-43%-0.273-44%-0.273-44%
Free Cash Flow To Equity Per Share--4.8760.937+420%0.784+522%0.888+449%0.888+449%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---32.490--------
Intrinsic Value_10Y_min---27.385--------
Intrinsic Value_1Y_max---1.460--------
Intrinsic Value_1Y_min---1.433--------
Intrinsic Value_3Y_max---5.756--------
Intrinsic Value_3Y_min---5.467--------
Intrinsic Value_5Y_max---11.701--------
Intrinsic Value_5Y_min---10.743--------
Market Cap3873842668.000-18%4576070886.7502818412484.688+62%1123836527.000+307%1400578274.058+227%1400578274.058+227%
Net Profit Margin----0%-0%0.547-100%0.547-100%
Operating Margin----0%-0%0.399-100%0.399-100%
Operating Ratio----0%-0%-0.5500%-0.5500%
Pb Ratio5.865-11%6.5325.664+15%3.690+77%3.517+86%3.517+86%
Pe Ratio-26.823+10%-29.876-21.583-28%-13.382-55%-14.047-53%-14.047-53%
Price Per Share66.070-11%73.59046.955+57%19.168+284%23.545+213%23.545+213%
Price To Free Cash Flow Ratio-34.000+10%-37.870-27.695-27%-17.027-55%-17.648-53%-17.648-53%
Price To Total Gains Ratio14.642-11%16.308-69.898+529%-40.551+349%-50.737+411%-50.737+411%
Quick Ratio--34.70536.442-5%42.480-18%35.195-1%35.195-1%
Return On Assets---0.052-0.060+15%-0.062+19%-0.132+153%-0.132+153%
Return On Equity---0.055-0.064+16%-0.065+19%-0.090+65%-0.090+65%
Total Gains Per Share--4.5130.842+436%0.759+495%0.867+421%0.867+421%
Usd Book Value--700561000.000490414750.000+43%305365250.000+129%284797000.000+146%284797000.000+146%
Usd Book Value Change Per Share--4.5130.842+436%0.759+495%0.867+421%0.867+421%
Usd Book Value Per Share--11.2668.194+37%5.208+116%4.805+134%4.805+134%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.616-0.529-14%-0.349-43%-0.340-45%-0.340-45%
Usd Free Cash Flow---30209000.000-24934750.000-17%-16242750.000-46%-16126692.308-47%-16126692.308-47%
Usd Free Cash Flow Per Share---0.486-0.418-14%-0.277-43%-0.273-44%-0.273-44%
Usd Free Cash Flow To Equity Per Share--4.8760.937+420%0.784+522%0.888+449%0.888+449%
Usd Market Cap3873842668.000-18%4576070886.7502818412484.688+62%1123836527.000+307%1400578274.058+227%1400578274.058+227%
Usd Price Per Share66.070-11%73.59046.955+57%19.168+284%23.545+213%23.545+213%
Usd Profit---38292000.000-30300250.000-21%-18606000.000-51%-19118692.308-50%-19118692.308-50%
Usd Revenue----0%-0%-187076.9230%-187076.9230%
Usd Total Gains Per Share--4.5130.842+436%0.759+495%0.867+421%0.867+421%
 EOD+2 -6MRQTTM+20 -9YOY+17 -125Y+19 -1210Y+19 -12

4.2. Fundamental Score

Let's check the fundamental score of Nuvalent Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-26.823
Price to Book Ratio (EOD)Between0-15.865
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than134.705
Current Ratio (MRQ)Greater than122.829
Debt to Asset Ratio (MRQ)Less than10.043
Debt to Equity Ratio (MRQ)Less than10.045
Return on Equity (MRQ)Greater than0.15-0.055
Return on Assets (MRQ)Greater than0.05-0.052
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Nuvalent Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.356
Ma 20Greater thanMa 5068.302
Ma 50Greater thanMa 10077.067
Ma 100Greater thanMa 20075.977
OpenGreater thanClose65.660
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -494192-302-1,235-1,537227-1,3101,34131



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets732,384
Total Liabilities31,823
Total Stockholder Equity700,561
 As reported
Total Liabilities 31,823
Total Stockholder Equity+ 700,561
Total Assets = 732,384

Assets

Total Assets732,384
Total Current Assets726,488
Long-term Assets5,896
Total Current Assets
Cash And Cash Equivalents 335,387
Short-term Investments 384,518
Other Current Assets 6,583
Total Current Assets  (as reported)726,488
Total Current Assets  (calculated)726,488
+/-0
Long-term Assets
Long-term Assets Other 5,896
Long-term Assets  (as reported)5,896
Long-term Assets  (calculated)5,896
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities31,823
Long-term Liabilities0
Total Stockholder Equity700,561
Total Current Liabilities
Accounts payable 9,274
Other Current Liabilities 22,549
Total Current Liabilities  (as reported)31,823
Total Current Liabilities  (calculated)31,823
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock7
Retained Earnings -286,296
Accumulated Other Comprehensive Income 31
Other Stockholders Equity 986,819
Total Stockholder Equity (as reported)700,561
Total Stockholder Equity (calculated)700,561
+/-0
Other
Capital Stock7
Cash and Short Term Investments 719,905
Common Stock Shares Outstanding 62,183
Liabilities and Stockholders Equity 732,384
Net Debt -335,387
Net Invested Capital 700,561
Net Working Capital 694,665



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
10,646
15,246
143,502
307,973
293,824
277,039
263,021
249,558
482,459
460,989
441,948
425,080
732,384
732,384425,080441,948460,989482,459249,558263,021277,039293,824307,973143,50215,24610,646000
   > Total Current Assets 
0
0
0
10,646
14,760
139,281
305,139
290,628
274,473
258,822
245,245
477,991
456,293
436,992
419,773
726,488
726,488419,773436,992456,293477,991245,245258,822274,473290,628305,139139,28114,76010,646000
       Cash And Cash Equivalents 
0
0
0
10,332
14,399
138,919
245,886
68,526
67,273
75,915
76,313
241,806
90,115
70,872
88,434
335,387
335,38788,43470,87290,115241,80676,31375,91567,27368,526245,886138,91914,39910,332000
       Short-term Investments 
0
0
0
0
0
0
56,543
219,585
205,461
181,049
163,751
230,357
360,347
360,367
324,824
384,518
384,518324,824360,367360,347230,357163,751181,049205,461219,58556,543000000
       Net Receivables 
0
0
0
0
0
0
2,834
3,196
0
0
0
4,468
0
0
0
0
00004,4680003,1962,834000000
       Other Current Assets 
0
0
0
314
361
362
2,710
2,517
1,739
1,858
5,181
5,828
5,831
5,753
6,515
6,583
6,5836,5155,7535,8315,8285,1811,8581,7392,5172,710362361314000
   > Long-term Assets 
0
0
0
0
486
4,221
2,834
3,196
2,566
4,199
4,313
4,468
4,696
4,956
5,307
5,896
5,8965,3074,9564,6964,4684,3134,1992,5663,1962,8344,2214860000
       Other Assets 
0
0
0
0
486
4,221
2,834
3,196
2,566
4,199
4,313
4,468
0
0
0
0
00004,4684,3134,1992,5663,1962,8344,2214860000
> Total Liabilities 
0
0
0
41,969
3,110
191,242
6,842
8,787
8,124
10,036
12,975
19,481
17,021
20,795
29,103
31,823
31,82329,10320,79517,02119,48112,97510,0368,1248,7876,842191,2423,11041,969000
   > Total Current Liabilities 
0
0
0
4,380
3,110
5,829
6,842
8,787
8,124
10,036
12,975
19,481
17,021
20,795
29,103
31,823
31,82329,10320,79517,02119,48112,97510,0368,1248,7876,8425,8293,1104,380000
       Accounts payable 
0
0
0
1,252
1,449
3,798
2,532
2,893
4,246
4,028
4,620
7,195
6,433
8,117
9,781
9,274
9,2749,7818,1176,4337,1954,6204,0284,2462,8932,5323,7981,4491,252000
       Other Current Liabilities 
0
0
0
3,128
1,661
2,031
4,310
5,894
3,878
6,008
8,355
12,286
10,588
12,678
19,322
22,549
22,54919,32212,67810,58812,2868,3556,0083,8785,8944,3102,0311,6613,128000
   > Long-term Liabilities 
0
0
0
37,589
1,449
185,413
2,532
2,893
4,246
4,028
4,620
7,195
6,433
0
0
0
0006,4337,1954,6204,0284,2462,8932,532185,4131,44937,589000
       Warrants
0
0
0
0
0
185,413
0
0
0
0
0
0
0
0
0
0
0000000000185,41300000
       Deferred Long Term Liability 
0
0
0
0
88
1,718
0
0
0
0
0
0
0
0
0
0
00000000001,718880000
> Total Stockholder Equity
0
0
0
-31,323
12,136
-47,740
301,131
285,037
268,915
252,985
236,583
462,978
443,968
421,153
395,977
700,561
700,561395,977421,153443,968462,978236,583252,985268,915285,037301,131-47,74012,136-31,323000
   Common Stock
0
0
0
0
2
0
5
5
5
5
5
6
6
6
6
7
7666655555020000
   Retained Earnings Total Equity000-185,269-160,077-133,954-114,238-95,772-78,223-60,934-48,50800000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-23
-228
-1,019
-1,132
-866
-494
-302
-1,537
-1,310
31
31-1,310-1,537-302-494-866-1,132-1,019-228-23000000
   Capital Surplus 
0
0
0
0
0
1,052
362,083
363,483
365,701
368,350
371,398
623,543
629,533
0
0
0
000629,533623,543371,398368,350365,701363,483362,0831,05200000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
562
50,804
-184,645
54,110
363,483
365,701
368,350
371,398
623,543
629,533
637,043
645,285
986,819
986,819645,285637,043629,533623,543371,398368,350365,701363,48354,110-184,64550,804562000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-149,492
Operating Income-149,492-149,492
 
Operating Expense (+$)
Research Development113,243
Selling General Administrative36,249
Selling And Marketing Expenses0
Operating Expense149,492149,492
 
Net Interest Income (+$)
Interest Income23,273
Interest Expense-23,273
Other Finance Cost-23,273
Net Interest Income23,273
 
Pretax Income (+$)
Operating Income-149,492
Net Interest Income23,273
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-126,219-172,765
EBIT - interestExpense = -23,273
-126,219
-102,946
Interest Expense23,273
Earnings Before Interest and Taxes (EBIT)0-102,946
Earnings Before Interest and Taxes (EBITDA)-149,492
 
After tax Income (+$)
Income Before Tax-126,219
Tax Provision-0
Net Income From Continuing Ops-114,050-126,219
Net Income-126,219
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses149,492
Total Other Income/Expenses Net23,273-23,273
 

Technical Analysis of Nuvalent
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nuvalent. The general trend of Nuvalent is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nuvalent's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Nuvalent Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 68.95 < 69.71 < 71.65.

The bearish price targets are: 49.64 > 49.02 > 41.16.

Tweet this
Nuvalent Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Nuvalent Inc. The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Nuvalent Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Nuvalent Inc. The current macd is -3.30263105.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nuvalent price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nuvalent. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nuvalent price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Nuvalent Inc Daily Moving Average Convergence/Divergence (MACD) ChartNuvalent Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Nuvalent Inc. The current adx is 39.14.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nuvalent shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Nuvalent Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Nuvalent Inc. The current sar is 62.20.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Nuvalent Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Nuvalent Inc. The current rsi is 39.36. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Nuvalent Inc Daily Relative Strength Index (RSI) ChartNuvalent Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Nuvalent Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nuvalent price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Nuvalent Inc Daily Stochastic Oscillator ChartNuvalent Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Nuvalent Inc. The current cci is -54.88483793.

Nuvalent Inc Daily Commodity Channel Index (CCI) ChartNuvalent Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Nuvalent Inc. The current cmo is -16.05990552.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Nuvalent Inc Daily Chande Momentum Oscillator (CMO) ChartNuvalent Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Nuvalent Inc. The current willr is -51.66760882.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Nuvalent is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Nuvalent Inc Daily Williams %R ChartNuvalent Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Nuvalent Inc.

Nuvalent Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Nuvalent Inc. The current atr is 3.00475666.

Nuvalent Inc Daily Average True Range (ATR) ChartNuvalent Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Nuvalent Inc. The current obv is 1,144,565.

Nuvalent Inc Daily On-Balance Volume (OBV) ChartNuvalent Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Nuvalent Inc. The current mfi is 28.84.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Nuvalent Inc Daily Money Flow Index (MFI) ChartNuvalent Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Nuvalent Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-20ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Nuvalent Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Nuvalent Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.356
Ma 20Greater thanMa 5068.302
Ma 50Greater thanMa 10077.067
Ma 100Greater thanMa 20075.977
OpenGreater thanClose65.660
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nuvalent with someone you think should read this too:
  • Are you bullish or bearish on Nuvalent? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nuvalent? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Nuvalent Inc

I send you an email if I find something interesting about Nuvalent Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Nuvalent Inc.

Receive notifications about Nuvalent Inc in your mailbox!